GlassScriptPhysician profile
Shubham Dixit
NPI 1932785367
$781.17
in general payments reported to CMS, 2019-2025
12 companies · $684 in 2025
The $684 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $97.20 · 2025: $684.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $781.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $781.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $283.16 | 2025 | Jardiance |
| Calliditas Therapeutics US INC. | $149.91 | 2025 | Tarpeyo |
| Novo Nordisk INC | $70.02 | 2025 | Ozempic, Rivfloza |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $43.04 | 2024 | |
| Genentech USA, INC. | $34.39 | 2025 | Gazyva |
| Mallinckrodt Hospital Products INC. | $33.48 | 2025 | Acthar |
| Alnylam Pharmaceuticals INC. | $32.19 | 2025 | Oxlumo |
| Amgen INC. | $29.89 | 2025 | Tavneos |
| Otsuka America Pharmaceutical, INC. | $28.61 | 2024 | Jynarque |
| Glaxosmithkline, LLC. | $28.49 | 2025 | Benlysta |
| Fresenius USA Marketing, INC. | $25.55 | 2024 | Velphoro |
| Scpharmaceuticals INC. | $22.44 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shubham Dixit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.